Allen Kaplan to Double-Blind Method
This is a "connection" page, showing publications Allen Kaplan has written about Double-Blind Method.
Connection Strength
0.250
-
Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study. J Am Acad Dermatol. 2018 04; 78(4):793-795.
Score: 0.108
-
Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol. 2005 Jun; 94(6):662-9.
Score: 0.046
-
Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2017 Oct; 31(10):1715-1721.
Score: 0.027
-
Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies. Ann Allergy Asthma Immunol. 2016 10; 117(4):370-377.e1.
Score: 0.025
-
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013 Mar 07; 368(10):924-35.
Score: 0.020
-
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011 Sep; 128(3):567-73.e1.
Score: 0.018
-
A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1999 Nov; 104(5):1071-8.
Score: 0.008